IMpassion130

NCT02425891 📎

Regimen

Experimental
Atezolizumab 840 mg D1,15 Q4W + nab-paclitaxel 100 mg/m2 D1,8,15 Q4W until progression or toxicity.
Control
Placebo + nab-paclitaxel.

Population

Previously untreated locally advanced or metastatic triple-negative breast cancer, no prior chemotherapy for metastatic disease.

Key finding

IMpassion130 was first positive IO trial in metastatic TNBC (atezo + nab-paclitaxel, PD-L1+ population) leading to initial FDA accelerated approval. Approval later withdrawn (Aug 2021) after IMpassion131 failed to confirm.

Source: PMID 30345906

Timeline

  • Publication: 2018 Nov 29

Guideline citations

  • NCCN BREAST